Landscapes / Targets
FGFR3
5 drugs act on FGFR3, in 14 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs5
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Infigratinibnot checked |
Tyrosine kinase inhibitor |
Phase 2/3 | Jan 2027Phase 2/3 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | Jan 2027 · Phase 2/3 trial completes | ||||
| Also tested for | Achondroplasia, Hypochondroplasia | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Eli Lilly · Public LLY |
Phase 3 | Jul 2028Phase 2 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | Jul 2028 · Phase 2 trial completes | ||||
| Also tested for | Urinary Bladder Neoplasms, Neoplasm Metastasis and 4 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Phase 2 | Nov 2026soonPhase 1/2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | Nov 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma and 15 more | ||||
| Open drug page | |||||
— |
Phase 1 | Mar 2027Phase 1 trial completes | |||
| Next date | Mar 2027 · Phase 1 trial completes | ||||
| Also tested for | Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma and 2 more | ||||
| Open drug page | |||||
— |
AstraZeneca +1 |
Phase 1 | — | ||
| Also tested for | Muscle Invasive Bladder Cancer | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 4 of 5 drugs. The other 1 is marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026